Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation

被引:31
|
作者
Taha, Maie S. [1 ,2 ,3 ]
Padmakumar, Smrithi [1 ]
Singh, Amit [4 ]
Amiji, Mansoor M. [1 ]
机构
[1] Northeastern Univ, Dept Pharmaceut Sci, Sch Pharm, 360 Huntington Ave, Boston, MA 02115 USA
[2] Harvard Med Sch, Massachusetts Eye & Ear Infirmary, 243 Charles St, Boston, MA 02114 USA
[3] Cairo Univ, Fac Pharm, Dept Pharmaceut & Ind Pharm, Cairo, Egypt
[4] Puretech Hlth, 6 Tide St, Boston, MA 02210 USA
关键词
Nanomedicine; Clinical translation; Drug delivery; Challenges; Nanoparticles; Quality attributes; Quality-by-design (QbD); NANOPARTICLE SURFACE-CHARGE; DRUG-DELIVERY SYSTEMS; PROTEIN CORONA; POLYMERIC NANOPARTICLES; DESIGN APPROACH; HYBRID NANOPARTICLES; LIPID NANOPARTICLES; IN-VITRO; PHYSICOCHEMICAL PROPERTIES; INORGANIC NANOPARTICLES;
D O I
10.1007/s13346-020-00744-1
中图分类号
TH7 [仪器、仪表];
学科分类号
0804 ; 080401 ; 081102 ;
摘要
Nanomedicine is a rapidly emerging field with several breakthroughs in the therapeutic drug delivery application. The unique properties of the nanoscale delivery systems offer huge advantages to their payload such as solubilization, increased bioavailability, and improved pharmacokinetics with an overall goal of enhanced therapeutic index. Nanomedicine has the potential for integrating and enabling new therapeutic modalities. Several nanoparticle-based drug delivery systems have been granted approval for clinical use based on their outstanding clinical outcomes. Nanomedicine faces several challenges that hinder the realization of its full potential. In this review, we discuss the critical formulation- and biological-related quality features that significantly influence the performance of nanoparticulate systems in vivo. We also discuss the quality-by-design approach in the pharmaceutical manufacturing and its implementation in the nanomedicine. A deep understanding of these nanomedicine quality checkpoints and a systematic design that takes them into consideration will hopefully expedite the clinical translation process. Graphical abstract
引用
收藏
页码:766 / 790
页数:25
相关论文
共 50 条
  • [31] Cannabis product critical safety attributes and critical quality attributes and good distribution practices
    Samann, Andrew
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258
  • [32] Performance-Based Quality Specifications: The Relationship Between Process Critical Control Parameters, Critical Quality Attributes, and Clinical Performance
    Short, Steven M.
    Cogdill, Robert P.
    Drennen, James K., III
    Anderson, Carl A.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 100 (04) : 1566 - 1575
  • [33] Recent Progress and Challenges in Clinical Translation of Nanomedicines in Diagnosis and Treatment of Lung Cancer
    Yadav, Bhavna
    Chauhan, Mahima
    Singh, Rahul Pratap
    Sonali
    Shekhar, Saurabh
    CURRENT DRUG TARGETS, 2024, 25 (01) : 12 - 24
  • [34] In depth characterization of physicochemical critical quality attributes of a clinical drug-dendrimer conjugate
    Sonzini, Silvia
    Caputo, Fanny
    Mehn, Dora
    Calzolai, Luigi
    Borgos, Sven Even
    Hyldbakk, Astrid
    Treacher, Kevin
    Li, Weimin
    Jackman, Mark
    Mahmoudi, Najet
    Lawrence, M. Jayne
    Patterson, Claire
    Owen, David
    Ashford, Marianne
    Akhtar, Nadim
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2023, 637
  • [35] Characterization of nanomedicines: A reflection on a field under construction needed for clinical translation success
    Coty, Jean-Baptiste
    Vauthier, Christine
    JOURNAL OF CONTROLLED RELEASE, 2018, 275 : 254 - 268
  • [36] Sound understanding of environmental, health and safety, clinical, and market aspects is imperative to clinical translation of nanomedicines
    Rosslein, Matthias
    Liptrott, Neill J.
    Owen, Andrew
    Boisseau, Patrick
    Wick, Peter
    Herrmann, Inge K.
    NANOTOXICOLOGY, 2017, 11 (02) : 147 - 149
  • [37] History and Clinical Development of Nanomedicines, Nanostructure, and Nanoscale Sciences
    Nazir, Taha
    Ahmed, Marya
    Mirza, Hameed
    Taha, Nida
    ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE, 2023, 29 (06) : 25 - 29
  • [38] Comparability of critical quality attributes for establishing biosimilarity
    Liao, Jason J. Z.
    Darken, Patrick F.
    STATISTICS IN MEDICINE, 2013, 32 (03) : 462 - 469
  • [39] Evaluation of Critical Quality Attributes of Dapsone Gel
    Kalami, Elmira
    Kahraman, Emine
    Dedeoglu, Ebru
    Gurbuz, Koray
    Ozsoy, Yildiz
    Gungor, Sevgi
    DISSOLUTION TECHNOLOGIES, 2023, 30 (01): : 30 - 35
  • [40] Quality attributes of recombinant therapeutic proteins: An assessment of impact on safety and efficacy as part of a quality by design development approach
    Eon-Duval, Alex
    Broly, Herve
    Gleixner, Ralf
    BIOTECHNOLOGY PROGRESS, 2012, 28 (03) : 608 - 622